LAS VEGAS, Nov. 7, 2024
The growing demand for respiratory disease testing is largely driven by the increasing global prevalence of respiratory disorders. Furthermore, the rising risk factors linked to these disorders, along with advancements in product development and regulatory approvals, are significant contributors to the expansion of the respiratory disease testing market from 2024 to 2030.
Advertisement
LAS VEGAS, Nov. 7, 2024 /PRNewswire/ -- DelveInsight's Respiratory Disease Testing Market Insights report provides the current and forecast market analysis, individual leading respiratory disease testing companies' market shares, challenges, respiratory disease testing market drivers, barriers, trends, and key market respiratory disease testing companies in the market.
Advertisement
Key Takeaways from the Respiratory Disease Testing Market Report
To read more about the latest highlights related to the respiratory disease testing market, get a snapshot of the key highlights entailed in the Global Respiratory Disease Testing Market Report
Respiratory Disease Testing Overview
Respiratory disease testing is a critical aspect of diagnosing and managing various conditions that affect the lungs and airways, including asthma, chronic obstructive pulmonary disease (COPD), and infections like pneumonia and COVID-19. These tests help in identifying the specific cause of respiratory symptoms, such as shortness of breath, coughing, or wheezing, and can range from non-invasive procedures like spirometry and pulse oximetry to more complex methods such as chest X-rays, CT scans, and bronchoscopy. Early and accurate diagnosis through these tests allows for timely treatment, which is essential in preventing complications, managing symptoms, and improving overall patient outcomes.
Advances in technology have significantly enhanced the accuracy and speed of respiratory disease testing. Molecular testing, such as polymerase chain reaction (PCR) tests, can detect respiratory pathogens with high sensitivity, allowing for the identification of viruses and bacteria in a matter of hours. In addition, new imaging techniques and portable diagnostic devices have made it easier to diagnose and monitor respiratory conditions in various settings, including at-home care. With the ongoing evolution of these testing methods, healthcare providers are better equipped to address the challenges of respiratory diseases, ultimately leading to more personalized and effective treatment plans.
Respiratory Disease Testing Market Insights
North America held the largest share of the respiratory disease testing market in 2023, driven by the increasing prevalence of respiratory diseases in the region. The rising incidence of respiratory disorders, coupled with strong research and development efforts and a highly viable market for product development and launches, are key factors contributing to the market's growth in North America.
As respiratory disorders become more common, the demand for diagnostic testing is expected to rise, further fueling market expansion in the United States and across North America. Moreover, significant product launches in the region are also positively influencing market growth. For example, in August 2023, BD received FDA clearance for its BD Respiratory Viral Panel (RVP) for the BD MAX™ System, a groundbreaking molecular diagnostic test that quickly identifies and differentiates SARS-CoV-2, influenza A, influenza B, and Respiratory Syncytial Virus (RSV) within approximately two hours.
In summary, the factors outlined above are expected to drive the overall growth of the respiratory disease testing market in North America throughout the forecast period.
To know more about why North America is leading the market growth in the respiratory disease testing market, get a snapshot of the Respiratory Disease Testing Market Outlook
Respiratory Disease Testing Market Dynamics
The respiratory disease testing market has undergone significant transformation over the past few years, driven primarily by the growing incidence of respiratory infections, advancements in diagnostic technologies, and the impact of the COVID-19 pandemic. The pandemic has especially highlighted the critical need for rapid and accurate diagnostic tests, propelling market growth and innovation. Governments and healthcare organizations worldwide have increased investments in respiratory disease testing infrastructure, further driving market expansion.
Technological advancements play a crucial role in shaping the dynamics of the respiratory disease testing market. The development of molecular diagnostic technologies, such as Polymerase Chain Reaction (PCR) and next-generation sequencing (NGS), has improved the accuracy and speed of disease detection. These advancements are not only essential for identifying common respiratory pathogens like influenza and respiratory syncytial virus but are also crucial in detecting emerging pathogens. Additionally, the integration of artificial intelligence (AI) and machine learning in diagnostic tools has enhanced the ability to interpret test results more accurately, thereby improving patient outcomes.
The market is also influenced by the increasing awareness and demand for point-of-care (POC) testing. POC tests offer the advantage of quick results, often within minutes, which is critical in managing and controlling respiratory diseases, particularly in pandemic situations. The convenience and speed of POC tests have led to their widespread adoption in various settings, including hospitals, clinics, and even home care. This trend is expected to continue, driven by the need for rapid diagnostics and the ongoing development of portable and easy-to-use testing devices.
However, the respiratory disease testing market faces challenges such as high costs associated with advanced diagnostic tests and regulatory hurdles. While innovations are rapidly evolving, the regulatory approval process can be lengthy and complex, potentially delaying the introduction of new products to the market. Moreover, disparities in access to testing, particularly in low- and middle-income countries, remain a significant concern, highlighting the need for affordable and accessible diagnostic solutions.
Get a sneak peek at the respiratory disease testing market dynamics @ Respiratory Disease Testing Market Dynamics Analysis
Report Metrics
Details
Coverage
Global
Study Period
2021–2030
Respiratory Disease Testing Market CAGR
~4%
Respiratory Disease Testing Market Size by 2030
~USD 9 Billion
Key Respiratory Disease Testing Companies
Koninklijke Philips N.V., Niterra Co., Ltd., Thermo Fisher Scientific Inc., QIAGEN, Abbott, Danaher Corporation, Siemens Healthineers, Diasorin S.p.A, BD, GE Healthcare, QuantuMDx Group Ltd., BIOMÉRIEUX, SDI Diagnostics, COSMED srl, Seegene Inc., CAREstream Medical Ltd., Bird Healthcare, visby medical, Vitalograph, Bio-Rad Laboratories, Inc., among others
Respiratory Disease Testing Market Assessment
Which MedTech key players in the respiratory disease testing market are set to emerge as the trendsetter explore @ Respiratory Disease Testing Companies
Table of Contents
1
Respiratory Disease Testing Market Report Introduction
2
Respiratory Disease Testing Market Executive Summary
3
Competitive Landscape
4
Regulatory Analysis
5
Respiratory Disease Testing Market Key Factors Analysis
6
Respiratory Disease Testing Market Porter's Five Forces Analysis
7
Respiratory Disease Testing Market Layout
8
Respiratory Disease Testing Market Company and Product Profiles
9
KOL Views
10
Project Approach
11
About DelveInsight
12
Disclaimer & Contact Us
Interested in knowing the respiratory disease testing market by 2030? Click to get a snapshot of the Respiratory Disease Testing Market Trends
Related Reports
Respiratory Drugs Market
Respiratory Drugs Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key respiratory drugs companies, including AstraZeneca, F. Hoffmann-La Roche Ltd., Teva Pharmaceuticals, Novartis AG, GSK plc., Merck & Co., Grifols, S.A., Boehringer Ingelheim International GmbH., Sanofi, Regeneron Pharmaceuticals Inc., Glenmark Pharmaceuticals Ltd., Lupin, Verona Pharma plc, Moderna, Inc., Pfizer Inc., among others.
Chronic Obstructive Pulmonary Disease Market
Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key chronic obstructive pulmonary disease companies, including Circassia Pharmaceuticals Inc., Theravance, Inc, Innoviva, Sunovion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, United Therapeutics, Verona Pharma PLC, Chiesi Farmaceutici S.p.A., Inmunotek, Tetherex Pharmaceuticals Corporation, Novartis Pharmaceuticals, Organicell Regenerative Medicine, GlaxoSmithKline, Novartis Pharmaceuticals, Vertex Pharmaceuticals Incorporated, Pulmotect Inc., GlaxoSmithKline, Genentech, Amgen, Mereo BioPharma, Biomarck Pharmaceuticals, among others.
Asthma Market
Asthma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key asthma companies, including GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Oneness Biotech Co., Ltd., Arrowhead Pharmaceuticals, Areteia Therapeutics, Jiangsu HengRui Medicine, SinoMab BioScience Ltd, Incyte Corporation, CSPC ZhongQi Pharmaceutical, Advagene Biopharma Co. Ltd., Beijing Kanova Biopharmaceutical, Inmunotek, Roche, Sanofi, ARS Pharmaceuticals, among others.
Severe Asthma Market
Severe Asthma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key severe asthma companies, including AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Inc., Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb, Eli Lilly and Company, Vertex Pharmaceuticals Incorporated, Amgen Inc., AbbVie Inc., Genentech, Inc., Gilead Sciences, Inc., Biogen Inc., CSL Limited, among others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us Shruti Thakur [email protected] +14699457679 https://www.delveinsight.com/medical-devices
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/global-respiratory-disease-testing-market-to-grow-at-a-cagr-of-4-by-2030--delveinsight-302298323.html
SOURCE DelveInsight Business Research, LLP
